Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing targeted small molecule therapies for RAS/MAPK pathway-driven cancers. Its pipeline includes RAF/MEK inhibitors, FAK inhibitors, and KRAS inhibitors, targeting solid tumors such as ovarian, lung, and pancreatic cancers. The company emphasizes innovative mechanisms, strategic partnerships, and regulatory pathways to improve treatment outcomes for patients with difficult-to-treat cancers.
This description was generated via AI from an annual report. Updated about 1 year ago.